Exploring a Nuclear-Selective Radioisotope Delivery System for Efficient Targeted Alpha Therapy

Targeted alpha therapy (TAT) has garnered significant interest as an innovative cancer therapy. Owing to their high energy and short range, achieving selective α-particle accumulation in target tumor cells is crucial for obtaining high potency without adverse effects. To meet this demand, we fabrica...

Descripción completa

Detalles Bibliográficos
Autores principales: Iizuka, Yuki, Manabe, Yoshiyuki, Ooe, Kazuhiro, Toyoshima, Atsushi, Yin, Xiaojie, Haba, Hiromitsu, Kabayama, Kazuya, Fukase, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253442/
https://www.ncbi.nlm.nih.gov/pubmed/37298546
http://dx.doi.org/10.3390/ijms24119593
Descripción
Sumario:Targeted alpha therapy (TAT) has garnered significant interest as an innovative cancer therapy. Owing to their high energy and short range, achieving selective α-particle accumulation in target tumor cells is crucial for obtaining high potency without adverse effects. To meet this demand, we fabricated an innovative radiolabeled antibody, specifically designed to selectively deliver (211)At (α-particle emitter) to the nuclei of cancer cells. The developed (211)At-labeled antibody exhibited a superior effect compared to its conventional counterparts. This study paves the way for organelle-selective drug delivery.

Ejemplares similares